The Director, Biomedical Research Center for Genetic Engineering and Biotechnology of the Island (IGBC), Gerardo Guillén, announced that in 2012 it will begin testing in patients with the therapeutic vaccine developed in Cuba against AIDS, forming the first phase assay in humans.
According to their statements, preliminary results will be announced during the working sessions of the 2012 Biotechnology Conference to be held until next March 8th.
The event is one of the most important worldwide for their high scientific level and call, which will focus on this occasion, the biomedical applications.
The scientific agenda also includes issues such as infectious diseases, neurodegeneration, like biology and cancer therapy.
For its part, Cuba will present advances in the production of prophylactic vaccines against dengue viral replication control, developments in the clinical outcomes of therapeutic drugs against hepatitis B and C as well as cancer, said Guillen.
Biotechnology 2012 began on Monday in the Convention Palace of Havana with the keynote of the 2003 Nobel Prize in Chemistry Peter Agre and participation of over 600 delegates from 39 countries.